Physician profile
Robert David Cook
NPI 1407813645
$13,292.58
in general payments reported to CMS, 2019-2025
35 companies · $2,959 in 2025
The $2,959 reported for 2025 was more than what 75% of Allergy & Immunology providers received nationally (typical 2025 total: $1,138).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,072 · 2020: $1,364 · 2021: $1,369 · 2022: $1,866 · 2023: $1,789 · 2024: $1,874 · 2025: $2,959.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $6,549 · Education: $40.77 · Consulting Fee: $32.24.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $6,548.91 |
| Education | $40.77 |
| Consulting Fee | $32.24 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $2,637.30 | 2019-2025 | Fasenra, Tezspire, Breztri |
| Glaxosmithkline, LLC. | $1,841.74 | 2019-2025 | Trelegy Ellipta, Nucala, Arexvy |
| Regeneron Healthcare Solutions, INC. | $1,556.40 | 2019-2025 | Dupixent |
| Genzyme Corporation | $1,279.08 | 2019-2025 | |
| Takeda Pharmaceuticals U.S.A., INC. | $992.39 | 2020-2025 | Cuvitru, Takhzyro, Eohilia |
| Csl Behring | $620.72 | 2019-2025 | Haegarda, Hizentra, Andembry |
| Genentech USA, INC. | $587.10 | 2019-2025 | Xolair |
| Novartis Pharmaceuticals Corporation | $568.75 | 2019-2025 | |
| Amgen INC. | $506.30 | 2021-2025 | Tezspire |
| Alk-Abello, INC | $492.29 | 2019-2025 | Grastek, Odactra, Ragwitek |
| Teva Pharmaceuticals USA, INC. | $271.68 | 2019-2021 | |
| Blueprint Medicines Corporation | $239.76 | 2023-2025 | Ayvakit |
| Kaleo, INC. | $220.88 | 2019-2024 | Auvi-Q |
| Grifols USA, LLC | $152.92 | 2021-2025 | Xembify, Gamunex-C |
| Galderma Laboratories, L.P. | $149.64 | 2025 | Nemluvio |
Show all 35 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Biocryst US Sales Co., LLC | $148.46 | 2021-2023 | Orladeyo |
| Ars Pharmaceuticals Operations, INC. | $142.09 | 2025 | Neffy |
| Octapharma USA, INC. | $110.41 | 2021-2025 | Panzyga, Cutaquig |
| Boehringer Ingelheim Pharmaceuticals, INC. | $105.66 | 2020-2025 | |
| Leo Pharma INC. | $93.43 | 2024 | Adbry |
| Pharming Healthcare, INC. | $81.54 | 2020-2022 | |
| Verona Pharma, INC. | $76.58 | 2025 | Ohtuvayre |
| Organon LLC | $64.92 | 2025 | Vtama |
| Shire North American Group INC | $59.47 | 2019 | |
| Insmed, INC. | $54.65 | 2025 | Arikayce, Brinsupri |
| Adma Biomanufacturing LLC | $48.59 | 2020-2025 | |
| Abbvie INC. | $35.97 | 2022-2023 | Rinvoq |
| Biocryst Pharmaceuticals, INC. | $33.84 | 2020 | |
| Lilly USA, LLC | $33.56 | 2024 | Ebglyss |
| Mylan Specialty L.P. | $17.17 | 2020 | |
| Gc Biopharma USA, INC. | $16.65 | 2024 | Alyglo |
| Pfizer INC. | $15.99 | 2023 | |
| Philips North America LLC | $13.80 | 2020 | |
| Aimmune Therapeutics, INC. | $11.70 | 2022 | |
| Merck Sharp & Dohme LLC | $11.15 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Robert Cook listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.